|
Back to products
Browse products
Approved anticancer agents
Anticancer agents in trials
Anticancer agents
in preclinical trials
Anticancer molecular libraries
Other drug agents
Drug intermediates
Bio-reagents and biochemicals
|
MedKoo product information:
GPX100
Description of GPX-100: GPX-100 is an analogue
of the anthracycline antineoplastic antibiotic doxorubicin. GPX-100
intercalates DNA and interacts with topoisomerase II, thereby inhibiting
DNA replication and repair and RNA and protein synthesis. GPX-100 was
designed to be a non-cardiotoxic anthracycline antibiotic. Check for
active clinical trials or
closed clinical trials using this agent. (NCI
Thesaurus).
Current developer:
Gem Pharmaceuticals, Inc and ACCESS Oncology, Inc.
|
MedKoo Code#: 201440
|
|
Name: GPX100
|
|
CAS#: 952648-77-0
Synonym:
GPX100; 13-deoxy-doxorubicin.
IUPAC/Chemical name:
(8R,10S)-10-(((2S,4S,5R,6S)-4-amino-5-hydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)-6,8,11-trihydroxy-8-(2-hydroxyethyl)-1-methoxy-7,8,9,10-tetrahydrotetracene-5,12-dione
|
|
Chemical structure |
Theoretical analysis
|
|
|
Chemical Formula: C27H31NO10
Exact Mass: 529.19480
Molecular Weight: 529.54
m/z: 529.19480 (100.0%), 530.19815 (29.2%),
531.20151 (4.1%), 531.19904 (2.1%)
Elemental Analysis: C, 61.24; H, 5.90; N,
2.65; O, 30.21
|
|
Availability and price:
This agent is not in stock, which may be available through custom synthesis.
To inquire quotation and lead time or to ask questions, please send email to
sales@medkoo.com to describe your needs. A representative
will respond your email shortly. We offer big discount for orders of bulk quantities.
|
|
Information about this agent
|
1: Slupe A, Williams B, Larson C, Lee LM,
Primbs T, Bruesch AJ, Bjorklund C, Warner DL, Peloquin J, Shadle SE,
Gambliel HA, Cusack BJ, Olson RD, Charlier HA Jr. Reduction of
13-deoxydoxorubicin and daunorubicinol anthraquinones by human carbonyl
reductase. Cardiovasc Toxicol. 2005 Fall;5(4):365-76. PubMed PMID:
16382174.
2: Parikh S, de Lemos JA. Current therapeutic strategies in cardiac
amyloidosis. Curr Treat Options Cardiovasc Med. 2005 Dec;7(6):443-8.
PubMed PMID: 16283971.
3: Almeida MR, Gales L, Damas AM, Cardoso I, Saraiva MJ. Small
transthyretin (TTR) ligands as possible therapeutic agents in TTR
amyloidoses. Curr Drug Targets CNS Neurol Disord. 2005 Oct;4(5):587-96.
Review. PubMed PMID: 16266291.
4: Efferth T, Oesch F. Oxidative stress response of tumor cells:
microarray-based comparison between artemisinins and anthracyclines.
Biochem Pharmacol. 2004 Jul 1;68(1):3-10. PubMed PMID: 15183112.
5: Cardoso I, Merlini G, Saraiva MJ. 4'-iodo-4'-deoxydoxorubicin and
tetracyclines disrupt transthyretin amyloid fibrils in vitro producing
noncytotoxic species: screening for TTR fibril disrupters. FASEB J. 2003
May;17(8):803-9. PubMed PMID: 12724338.
6: Gertz MA, Lacy MQ, Dispenzieri A, Cheson BD, Barlogie B, Kyle RA,
Palladini G, Geyer SM, Merlini G. A multicenter phase II trial of
4'-iodo-4'deoxydoxorubicin (IDOX) in primary amyloidosis (AL). Amyloid.
2002 Mar;9(1):24-30. PubMed PMID: 12000194.
7: Gambliel HA, Burke BE, Cusack BJ, Walsh GM, Zhang YL, Mushlin PS,
Olson RD. Doxorubicin and C-13 deoxydoxorubicin effects on ryanodine
receptor gene expression. Biochem Biophys Res Commun. 2002 Mar
1;291(3):433-8. PubMed PMID: 11855807.
8: Sebastião MP, Merlini G, Saraiva MJ, Damas AM. The molecular
interaction of 4'-iodo-4'-deoxydoxorubicin with Leu-55Pro transthyretin
'amyloid-like' oligomer leading to disaggregation. Biochem J. 2000 Oct
1;351(Pt 1):273-9. PubMed PMID: 10998371; PubMed Central PMCID:
PMC1221359.
9: Findeis MA. Approaches to discovery and characterization of
inhibitors of amyloid beta-peptide polymerization. Biochim Biophys Acta.
2000 Jul 26;1502(1):76-84. Review. PubMed PMID: 10899433.
10: Palha JA, Ballinari D, Amboldi N, Cardoso I, Fernandes R, Bellotti
V, Merlini G, Saraiva MJ. 4'-Iodo-4'-deoxydoxorubicin disrupts the
fibrillar structure of transthyretin amyloid. Am J Pathol. 2000
Jun;156(6):1919-25. PubMed PMID: 10854215; PubMed Central PMCID:
PMC1850080.
11: Pérez Equiza E, Arguiñano JM, Gastearena J. Successful treatment of
AA amyloidosis secondary to Hodgkin's disease with 4'-iodo-4'-deoxydoxorubicin.
Haematologica. 1999 Jan;84(1):93-4. PubMed PMID: 10091401.
12: Merlini G, Anesi E, Garini P, Perfetti V, Obici L, Ascari E, Lechuga
MH, Capri G, Gianni L. Treatment of AL amyloidosis with 4'-lodo-4'-deoxydoxorubicin:
an update. Blood. 1999 Feb 1;93(3):1112-3. PubMed PMID: 10025983.
|
Contact MedKoo:
Email:
sales@medkoo.com
(Keyword; CAS#; MedKoo code#)
|
